Drugs / TBI-1401(HF10)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03252808 | Sep 2017 → Feb 2020 overdue | pancreatic ductal adenocarcinoma | Takara Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02428036 | Jun 2015 → Oct 2016 | neoplasm | Takara Bio Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03153085 | May 2017 → Jun 2018 | melanoma | Takara Bio Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI-1401(HF10) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03252808 ↗ |
| Known as | HF10 | “The purpose of this study is to determine whether TBI-1401(HF10), a spontaneously attenuated mutant of Herpes Simplex Virus Type 1 (HSV-1), is safe and tolerable in the...” NCT02428036 ↗ |
| Modality | Other / unclassified | “Replication-competent HSV-1 Oncolytic Virus” NCT03153085 ↗ |
| Route | Other | “intratumoral administrations” NCT02428036 ↗ |